Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.

Fifteen post-menopausal patients with advanced breast cancer were treated with the LH-RH agonist leuprorelin (D-leu6-des-gly10-Gn-RH-ethylamide) given in a dosage of 7.5 mg as a monthly subcutaneous depot injection, to assess the clinical activity and endocrine response to treatment. None of the 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Crighton, I. L., Dowsett, M., Lal, A., Man, A., Smith, I. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247121/
https://www.ncbi.nlm.nih.gov/pubmed/2508735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247121/
https://www.ncbi.nlm.nih.gov/pubmed/2508735

Ejemplares similares